LOXO-195 promising against tumors with acquired resistance to first-generation therapeutics
ATLANTA -- The investigational anticancer therapeutic LOXO-195 (now known as BAY 2731954), which targets a family of proteins called TRKs, was safe, tolerable, and showed...





